Holen Sie sich die Stockscreener-App
81.53
1.57%
1.26
Handel nachbörslich:
83.00
1.47
+1.80%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$80.27
Offen:
$79.515
24-Stunden-Volumen:
5.19M
Relative Volume:
1.23
Marktkapitalisierung:
$32.67B
Einnahmen:
$4.15B
Nettoeinkommen (Verlust:
$535.20M
KGV:
60.84
EPS:
1.34
Netto-Cashflow:
$575.20M
1W Leistung:
+14.35%
1M Leistung:
+36.27%
6M Leistung:
+18.83%
1J Leistung:
-37.12%
1-Tages-Spanne:
$78.55
$82.48
1-Wochen-Bereich:
$69.70
$82.48
52-Wochen-Spanne:
$57.52
$132.26
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
81.53 | 32.67B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
133.06 | 227.05B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.12 | 152.00B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
377.52 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.32 | 108.50B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.92 | 44.68B | 5.54B | 4.18B | 259.90M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
William Blair Issues Negative Estimate for DexCom Earnings - Defense World
Oura, Dexcom Release Glucose App Linked with Stelo CGM - Medical Product Outsourcing
ŌURA rolls out glucose app linked with Dexcom’s CGM Stelo - Yahoo Finance
Dexcom expands Oura partnership with Stelo integration - MassDevice
Your Oura Ring can now track meals and monitor glucose levels - Mashable
DexCom (NASDAQ:DXCM) Price Target Raised to $93.00 at Barclays - Defense World
Wait For A Dip To Buy DexCom Stock - Nasdaq
Barclays Adjusts DexCom Price Target to $93 From $90, Maintains Equal Weight Rating - marketscreener.com
DexCom (DXCM) Gets Price Target Increase from Barclays | DXCM Stock News - GuruFocus
Should You Buy DXCM Stock At $80? - Forbes
Dexcom revenue grows 12% to USD 1.036 billion in Q1 2025 - Medical Buyer
Barclays Adjusts Price Target for DexCom (DXCM) to $93 Following Q1 Results | DXCM Stock News - GuruFocus
DexCom Stock: Growth Is Reaccelerating But Don't Ignore The Risks (NASDAQ:DXCM) - Seeking Alpha
DexCom (DXCM) Shares Surge on Strong Revenue and Buyback Announcement - GuruFocus
Dexcom Stock Is Today’s Big Winner After Earnings. Why the Medtech is Soaring. - Barron's
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Why DexCom Inc. (DXCM) Soared Last Week - MSN
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationDXCM - ACCESS Newswire
Dexcom announces 15-day G7 system launch for H2 2025 amid strong Q1 revenue growth - MSN
Investors who lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Market Indexes Rise On Strong Payroll Data; DexCom Leads Gains - Finimize
Why DexCom, Inc. (DXCM) Went Up On Friday - Insider Monkey
BTIG raises DexCom stock price target to $109 from $107 By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
DexCom Stock Rockets Higher To Lead S&P 500 Gainers Friday - Investopedia
DexCom (NasdaqGS:DXCM) Announces US$750M Buyback and Reiterates 2025 Earnings Guidance - Yahoo Finance
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins - Zacks Investment Research
DexCom (DXCM) Stock Rating Maintained, Price Target Lowered | DXCM Stock News - GuruFocus
Leerink Adjusts Price Target on DexCom to $101 From $95 - marketscreener.com
Top Stock Movers Now: Dexcom, Berkshire Hathaway, Nvidia, and More - Investopedia
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
DexCom (DXCM): Analyst Maintains Rating but Lowers Price Target - GuruFocus
DexCom (DXCM): Analyst Maintains Rating but Lowers Price Target | DXCM Stock News - GuruFocus
Redburn Atlantic Adjusts DexCom Price Target to $110 From $115 - marketscreener.com
DexCom (DXCM) Target Price Reduced by Baird Amid Mixed Q1 Result - GuruFocus
DexCom, Inc. (NASDAQ:DXCM) Q1 2025 Earnings Call Transcript - Insider Monkey
DexCom (DXCM) Target Price Reduced by Baird Amid Mixed Q1 Results | DXCM Stock News - GuruFocus
DexCom (DXCM) Sees Improved Price Target Following Strong Q1 Per - GuruFocus
DexCom (DXCM) Price Target Increased by Canaccord Following Stro - GuruFocus
DexCom (DXCM) Sees Improved Price Target Following Strong Q1 Performance | DXCM Stock News - GuruFocus
DexCom (DXCM) Price Target Lowered by Piper Sandler | DXCM Stock News - GuruFocus
DexCom (DXCM) Price Target Increased by Canaccord Following Strong Q1 Results | DXCM Stock News - GuruFocus
Decoding DexCom Inc (DXCM): A Strategic SWOT Insight - GuruFocus
DexCom Inc (DXCM) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - Yahoo Finance
DexCom Inc (DXCM) Q1 2025 Earnings: Revenue Surpasses Estimates - GuruFocus
DXCM STOCK ALERT: A Class Action is Pending Against DexCom, Inc. for Securities Fraud; Contact BFA Law before October 21 Court Deadline if You Lost Money - ACCESS Newswire
Dexcom Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Dexcom Reports Strong Q1 2025 Results and Strategic Growth - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.29%
1.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):